State Key Laboratory of Natural Medicines, Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Nanjing Foreign Language School, Nanjing 210008, China.
Eur J Med Chem. 2017 Aug 18;136:63-73. doi: 10.1016/j.ejmech.2017.04.074. Epub 2017 Apr 30.
Identification of novel Hsp90 inhibitors to disrupt Hsp90-Cdc37 protein-protein interaction (PPI) could be an alternative strategy to achieve Hsp90 inhibition. In this paper, a series of small molecules targeting Hsp90-Cdc37 complex are addressed and characterized. The molecules' key characters are determined by utilizing a structure-based virtual screening workflow, derivatives synthesis, and biological evaluation. Structural optimization and structure-activity relationship (SAR) analysis were then carried out on the virtual hit of VS-8 with potent activity, which resulted in the discovery of compound 10 as a more potent regulator of Hsp90-Cdc37 interaction with a promising inhibitory effect (IC = 27 μM), a moderate binding capacity (K = 40 μM) and a preferable antiproliferative activity against several cancer lines including MCF-7, SKBR3 and A549 cell lines (IC = 26 μM, 15 μM and 38 μM respectively). All the data suggest that compound 10 exhibits moderate inhibitory effect on Hsp90-Cdc37 and could be regard as a first evidence of a non-natural compound targeting Hsp90-Cdc37 PPI.
鉴定新型 HSP90 抑制剂以破坏 HSP90-Cdc37 蛋白-蛋白相互作用(PPI)可能是实现 HSP90 抑制的另一种策略。在本文中,我们针对 HSP90-Cdc37 复合物设计并表征了一系列小分子。这些分子的关键特征是通过利用基于结构的虚拟筛选工作流程、衍生物合成和生物评估来确定的。然后,对具有强大活性的虚拟命中物 VS-8 进行了结构优化和构效关系(SAR)分析,结果发现化合物 10 是一种更有效的 HSP90-Cdc37 相互作用调节剂,具有有希望的抑制作用(IC=27μM)、适度的结合能力(K=40μM)和对包括 MCF-7、SKBR3 和 A549 细胞系在内的几种癌细胞系的较好的抗增殖活性(IC=26μM、15μM 和 38μM)。所有数据表明,化合物 10 对 HSP90-Cdc37 具有适度的抑制作用,可作为靶向 HSP90-Cdc37 PPI 的非天然化合物的首例证据。